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Background: Several classification systems are available to assess pathological response to neoadjuvant
chemotherapy in breast cancer, but reliable biomarkers to predict the efficiency of primary systemic therapy (PST)
are still missing. Deregulation of gap junction channel forming connexins (Cx) has been implicated in
carcinogenesis and tumour progression through loss of cell cycle control. In this study we correlated Cx expression
and cell proliferation with disease survival and pathological response to neoadjuvant chemotherapy in breast
cancers using existing classification systems.
Methods: The expression of Cx26, Cx32, Cx43, Cx46 and Ki67 was evaluated in 96 breast cancer patients prior to
and after neoadjuvant chemotherapy using duplicate cores in tissue microarrays (TMA). Cx plaques of <1μm were
detected with multilayer, multichannel fluorescence digital microscopy. Current classifications to assess residual
tumour burden after primary systemic therapy included the EWGBSP, CPS-EG, Miller-Payne, Sataloff and NSABP
systems.
Results: In our cohort dominated by hormone receptor (ER/PR) positive and HER2 negative cases, only the CPS-EG
classification showed prognostic relevance: cases with scores 1–2 had significantly better overall survival (p=0.015)
than cases with scores 3–5. Pre-chemotherapy Cx43 expression correlated positively with hormone receptor status
both before and after chemotherapy and had a negative correlation with HER2 expression pre-chemotherapy.
There was a positive correlation between Cx32 and HER2 expression pre-chemotherapy and between Cx32 and
Ki67 expression post-chemotherapy. A negative correlation was found between post-chemotherapy Cx46 and Ki67
expression. Decreased post-chemotherapy Cx26 expression (<5%) statistically correlated with better overall survival
(p=0.011). Moderate or higher Cx46 expression (>20%) pre- and post-chemotherapy correlated with significantly
better survival in the intermediate prognostic subgroups of EWGBSP TR2b (ppre-chemo=0.006; Sataloff TB
(ppre-chemo=0.005; ppost-chemo=0.029) and in Miller-Payne G3 (ppre-chemo=0.002; ppost-chemo=0.012) classifications.
Pre-chemotherapy, Cx46 expression was the only marker that correlated with overall survival within these subgroups.
Conclusion: Our results suggest that Cx46 and Cx26 expression in breast cancer may improve the assessment of
pathological response and refine intermediate prognostic subgroups of residual tumour classifications used after
neoadjuvant chemotherapy.
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Despite of mammographic screening, early diagnosis and
available targeted therapy, breast cancer is still one of the
most frequent cause of tumour related death of women in
the western world [1]. Molecular subtyping and related
new therapeutic approaches require diagnostic screening
for at least the hormone receptors (ER, PR) and HER2
overexpression/gene amplification as predictive and prog-
nostic markers [2]. To date several classifications have been
developed to assess pathologic response to neoadjuvant
chemotherapy. Most systems are based on the amount
of residual tumour in the breast and the axilla [3-7]. The
recently described CPS-EG score combines clinical and
pathological stage with nuclear grade and hormone recep-
tor status [8,9]. However, reliable biomarkers to prognosti-
cate response to primary systemic therapy (PST) are
still missing.
The gap junction forming connexins (Cx) mediate direct
cell-cell communication and their dysfunction can contrib-
ute to carcinogenesis and tumour progression in a wide
range of neoplasias including breast cancer [10]. Connexins
form gap junction channels that allow the regulated trans-
port of <1.5kDa molecules, including secondary messengers
(Ca2+, cAMP, IP3), metabolites (ATP, NAD+, small peptides
and nucleotides) between adjacent cells [11] to coordinate
functions within cell compartments [12]. They are abun-
dant in all human solid tissues and more than one isotype -
of the 21 cloned human isotypes - are found in most cell
types [13]. Connexins play crucial roles in cell homeostasis
including of regulation of cell growth, proliferation and
apoptosis, either as gap junctions, hemichannels or through
protein-protein interactions [14,15]. Therefore, functional
Cx can be localized both to the cell membrane and the
cytoplasm [16]. In normal mammary epithelium, Cx43 has
been found in the myoepithelial cells and Cx26 in the lu-
minal epithelium [17].
Connexins and gap junctions have been linked to car-
cinogenesis through aberrant expression and functions
[18]. They show tumour stage dependent expression and
may play opposing roles during breast cancer progression
[19]. Connexin expression is usually down-regulated upon
malignant transformation, but it can also mediate tumour
cell endothelial interactions during tumour diapedesis
[20]. Cx43 and Cx26 can be involved in tumour suppres-
sion in early stage breast cancer, but these connexins and
Cx32 may also support metastatic tumour colonization by
upregulation in the lymph nodes [21-23]. Moreover, new
connexin isotypes such as Cx46 can appear in breast can-
cer, which may assist MCF-7 breast cancer cells in
adapting to hypoxia [24].
The aim of this study was to correlate connexin ex-
pression and cell proliferation with clinicopathological
parameters (stage, ER, PR and HER2) and prognosis in
breast cancer patients treated with PST. Of the 15 of 21connexin isotypes (Cx23, Cx26, Cx30, Cx30.2, Cx30.3,
Cx31, Cx31.1, Cx32, Cx36, Cx37, Cx43, Cx45, Cx46,
Cx50 and Cx62) tested in a pilot study Cx26, Cx32,
Cx43 and Cx46 were detected reliably and widespread in
breast cancers. These isotypes were screened together
with Ki67 expression prior to- (pre-chemo) and after
neoadjuvant chemotherapy (post-chemo) using whole-
slide immunofluorescence digital microscopy in 96
breast cancers included in tissue microarrays (TMA).
Results were correlated with subgroups of the current
classifications including the CPS-EG score (Clinical
Pathological Stage combined with Estrogen receptor sta-
tus and Grade by M.D. Anderson Cancer Center, Texas),
NSABP (National Surgical Adjuvant Breast and Bowel
Project), Miller-Payne ‘G’, Sataloff ‘T’ and EWGBSP ‘TR’
(European Working Group for Breast Screening Path-
ology) systems [3-9]. Our results suggest the potential
prognostic value of Cx detection in neoadjuvant treated
breast cancer. Cases with reduced Cx26 expression post-
chemotherapy and those with moderate to high Cx46
expression both pre- and post-chemotherapy showed
significantly improved survival rates particularly in the
intermediate subgroups of current classification systems.
Methods
Patient cohort
96 patients with breast cancer, diagnosed either in core
biopsies or fine needle aspiration biopsy (FNAB) and
then treated with neoadjuvant chemotherapy were
selected consecutively between 1998 and 2009 from the
archives of the Institute of Surgical Pathology, University
Hospital Zurich, Switzerland. Chemotherapy regimens
included Docetaxel 75 mg/m2; Epirubicin 90 mg/m2;
Cyclophosphamide 500 mg/m2; Doxorubicin 50 mg/m2;
Vinorelbine 30 mg/m2; Fluorouracil 500 mg/m2; and also
Trastuzumab (250 mg/m2). The exact preoperative chemo-
therapy schedules were available in 73 patients (Docetaxel/
Epirubicin n=24, Epirubicin/Cyclophosphamide /Fluorouracil
n=23, Docetaxel/Epirubicin/Cyclophosphamide n=14, Doce-
taxel/Trastuzumab n=7, Vinorelbine/Trastuzumab n=5).
Chemotherapy schedules were administered in 2 to 6
cycles.
Formalin-fixed, paraffin-embedded (FFPE) tumour
blocks from preoperative core biopsies and from the
corresponding postoperative tissues were available in 64
patients. Core biopsies prior to neoadjuvant chemotherapy
without surgical specimens after chemotherapy were available
in 17 patients. Surgical specimens following the chemother-
apy without previous core biopsies (diagnosed with FNAB)
were available in 15 patients. Clinicopathological and follow-
up data (2 to 10 years) on 96 patients could be retrieved from
the pathological and clinical files as summarized in Table 1.
Histologically or cytologically 75 tumours (78%) were
diagnosed as invasive ductal carcinoma, 18 (19%) as invasive
Table 1 Clinicopathological features of breast cancer patients studied
n=96 Prior to chemotherapy After chemotherapy
Tumour size 1,5-13 cm 0,3-14 cm
cT1 1 (1%) ypT0 6 (6%)
-a ypT1 20 (21%)
-b -a 2
-c 1 -b 11
cT2 25 (26%) -c 7
cT3 22 (23%) ypT2 31 (32%)
cT4 41 (43%) ypT3 24 (25%)
-b 19 ypT4 7 (7%)
-d 22 -b 6
NA 7 (7%) -d 1
No surgery 8 (9%)
Lymph node status cN0 10 (11%) pN0 25 (26%)
cN1 62 (64%) pN1 27 (28%)
cN2 pN2 12 (12%)
cN3 3 (3%) pN3 14 (15%)
No surgery 8 (9%)
NA 21 (22%) NA 10 (10%)
ER status Positive 68 (71%) Positive 59 (62%)
Negative 25 (26%) Negative 16 (17%)
NA 3 (3%) NA 21 (21%)
ypT0, no surgery
PR status Positive 59 (62%) Positive 46 (48%)
Negative 34 (35%) Negative 29 (31%)
NA 3 (3%) NA 21 (21%)
ypT0, no surgery
HER2 status Positive 28 (29%) Positive 18 (19%)
Negative 65 (68%) Negative 57 (60%)
NA 3 (3%) NA 21 (21%)
ypT0, no surgery
Ki67 status 0 2 (2%) 0 22 (28%)
1 (0-1%) 12 (15%) 1 21 (27%)
2 (1-5%) 19 (23%) 2 11 (14%)
3 (5-10%) 13 (16%) 3 3 (4%)
4 (10-15%) 6 (7%) 4 1 (1%)
5 (15-20%) 4 (5%) 5 6 (8%)
6 (20-33%) 2 (2%) 6 1 (1%)
7 (33-50%) 4 (5%) 7 2 (3%)
8 (50-66%) 1 (1%) 8 0 (0%)
9 (66-80%) 3 (4%) 9 3 (4%)
10 (80-100%) 1 (1%) 10 2 (3%)
NA 14 (17%) NA 7 (9%)
P
64+17 (100%)
P
64+15 (100%)
NA: Accurate data are not available.
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carcinomas (2%) and one case was a small cell carcinoma.
Patient’s age ranged from 30 to 74 years (mean age: 52 years).
Eight of 96 patients (9%) had multifocal tumours on imaging.
Histological grading according to the modified Bloom-
Richardson score could be done in 81 cases: 38 cases (40%)
were poorly differentiated (grade 3) carcinomas, 42 (44%)
moderately differentiated (grade 2), one case (1%) was well
differentiated (grade 1), 15 cases (15%) had only small
amount of tumour tissue insufficient for correct grading on
the core [25].
Mastectomy was performed in 60 patients (62%) and
segmentectomy in 28 patients (29%). Breast surgery was
completed with axillary dissection in all but 5 of these
patients. In 8 patients (9%) either no surgery was
performed or we had no records in our files. Fifteen of 96
patients (16%) had multifocal tumours at the time of sur-
gery. Tumour cellularity was estimated as the percentage
of residual tumour cells distributed in the tumour bed
area [6]. The histological subtypes were identical to those
of the preoperative biopsies. The frequency of ER/PR and
HER2 positive cases in our cohort roughly reflected that
of the general breast cancer population.
The study and the construction of TMA was approved
by the Ethical Committee of the Canton Zurich (KEK-
ZH NR: 2009–0065) and also by the Internal Review
Board of the Institute of Surgical Pathology.
Detection of hormone receptors and HER2
Estrogen receptor (ER, clone 6F11) and progesterone re-
ceptor (PR, clone 1A6) expression was determined using
the iVIEW DAB detection kit in Ventana Benchmark
(all from Ventana, Basel, Switzerland) immunostainer
following heat induced epitope retrieval in CC1 solution.
Cases of >1% nuclear positive tumour cells were
considered as positive [25].
HER2 status was defined according to the initial and the
modified ASCO criteria using immunohistochemistry
and/or fluorescence in situ hybridization (FISH) (1998–
2004 IHC and FISH, 2004–2009 only FISH) [26].
Between 1998-2004 the Pathway™ HER2 (clone CB11)
FDA approved kit (Ventana) was used for automated
immunostaining as described above. Cases with tumour
cells of >10% strong and complete membrane staining
were considered 3+; and those with >10% moderate, but
complete membrane staining as 2+ requiring additional
FISH testing. During the 1998–2009 period HER2 gene
amplification was tested using the dual colour FISH kit
of PathVision (Vysis, Abbott AG, Baar, Switzerland)
according to the manufacturer’s protocol.
Tissue microarray construction
Hematoxylin-eosin (H&E) stained sections of all FFPE
tumours were re-evaluated by one pathologist (Z.V.) forsuitability for TMA, which were prepared as described
earlier containing duplicate cores from each patient’s
samples [27,28]. Core biopsies from 81 patients prior to
chemotherapy (64 matched surgical and core biopsy;
and 17 core biopsy only) and tumour samples from 79
patients after chemotherapy (64 paired as above and 15
surgical) were arrayed into two TMA blocks.
Immunofluorescence detection of connexins
TMA slides of 4 μm thick were dewaxed in xylene and
rehydrated through ethanol series. Antigen unmasking
was done in a 0.1 M Tris 0.01 M EDTA buffer (pH 9.0)
using an electric pressure cooker (Avair, Biofa, Veszprem,
Hungary) for 20 min at ~105 C followed by 10 sec diges-
tion in 0,25% Gibco trypsin phenol red (1:50; Life Tech-
nologies, Carlsbad, CA, Ref: 25050–014). After a protein
blocking step for 20 min the slides were incubated over-
night using rabbit anti-mouse Cx26 (1:4000, AB8143,
Millipore, Billerica, MA) or anti-human Cx32 (1:30,
HPA010663, Sigma-Aldrich, St Luis, MO), Cx43 (1:100,
#3512, Cell Signaling, Beverly, MA) or Cx46 (1:100,
SAB13005557, Sigma-Aldrich) antibodies. All animal spe-
cific connexin antibodies used highly cross-react with the
relevant human connexins [29]. TMA slides were simul-
taneously also stained for Ki-67 protein using the mouse
anti-human Mib-1 antibody (1:2 ready-to-use, IR626,
Dako, Glostrup, Denmark).
Fluorochrome-labelled secondary antibodies, Alexa
Fluor 546 (red) goat anti-rabbit IgG (A11035) and Alexa
Fluor 488 (green) goat anti-mouse IgG (A11001) were ap-
plied in 1:200 for 90 min. Finally, Hoechst (1:1000, B2883,
blue) was used for nuclear staining (all from Invitrogen-
Life technologies, Eugene, OR), for 60 sec. All incubations
were done in a humid chamber at room temperature
and slides were washed between the steps using 0.1 M
TBS (Tris-buffered saline) pH 7.4 for 2x5 min. Immu-
nostained slides were digitalized using Pannoramic Scan
(3DHISTECH Ltd., Budapest, Hungary). The multilayer,
multichannel fluorescence digitalization of TMA slides
resulted in permanent fluorescence samples and allowed
accurate analysis of connexin plaques of frequently <1μm
size within the whole section thickness without the risk
of false negativity due to fading or lack of focus depth
resolution.
Scoring of connexin expression and cell proliferation
Immunoreactions for Cx-s were evaluated by two inde-
pendent assessors using a 4-scale scoring system with
the TMA module software [30] (3DHISTECH) by
considering the frequency of positively stained cells as
follows: score 0: <5%; score 1: 5-20%; score 2: 20-60%;
score 3: >60%). Positive signals of all assessed connexin
subtypes were localized in the plasma membrane in the
normal breast epithelial cells. In breast cancer samples,
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the invasive tumour cells. Both of these signal types were
considered upon scoring. Stromal, smooth muscle and
endothelial cells, adipocytes, skin, keratinocytes and nor-
mal mammary epithelium served as endogenous positive
controls. Ki-67 reaction was assessed on a linear 0–10 scale
(score 0: 0, 1: 0-1%, 2: 1-5%, 3: 5-10%, 4: 10-15%, 5:15-20%,
6: 20-33%, 7: 33-50%, 8: 50-66%, 9: 66-80%, 10: 80-100%)
considering the frequency of positive tumour cells (Table 1).
In case of tumour heterogeneity the higher score was
considered for statistics.
Assessing tumour response after neoadjuvant
chemotherapy using histopathological and clinical
classification systems
Five current pathological classification systems were
applied retrospectively to assess pathologic response
after neoadjuvant chemotherapy. Four of these systemsTable 2 Definition of classification systems and distribution o
Classification system Cases
NSABP pCR 5 No histo
pINV 84 Histologica
Miller-Payne G1 10 Some alteration to individual malign
G2 20 A minor loss of invas
G3 40 A moderate reduction
G4 14 A marked disappearance of invasive tu
G5 5 No invasive tumours
Sataloff TA 20 To
TB 30 Subjectively greater th
TC 29 Less tha
TD 10
EWGBSP TR1a 4
TR1b 1 No residual invasiv
TR2a 14 Min
TR2b 31 Therapeutic
TR2c 29 Therapeut
TR3 10
CPS-EG 0 0
1 2 Clinical stage Path
2 19 I; IIA = 0
3 17 IIB; IIIA = 1 IIA/B
4 12 IIIB; IIIC = 2
5 5
6 0
1NSABP: National Surgical Adjuvant Breast and Bowel Project
2EWGBSP: European Working Group for Breast Screening Pathology
3CPS-EG: Clinical Pathological Stage combined with Estrogen receptor status and Gr
4G3: gradeNSABP, Miller-Payne Grade, Sataloff T and EWGBSPTR
analyse the extent of residual tumour tissue (none, in
situ or invasive). These could be applied retrospectively
in 89 cases. The CPS-EG score classification combines
clinical and pathological stages with nuclear grading and
hormone receptor expression, which could be used in 55
cases. Details of pathological response and definition of
classification systems are summarized in Table 2.
Statistical analysis
SPSS 15.0 software was used for statistical comparisons
(SPSS, Inc., Chicago, IL, USA). Categorical data were analysed
using chi-square test. Spearman rank correlation was used to
correlate connexin scores and clinicopathological parameters
(stage and grade, hormone receptor status, HER2 status).
Overall survival was calculated using Kaplan-Meier method
with assessment of statistical significance by log-rank test.
For multivariate analysis Cox-regression analysis with 95%f the enrolled cases
Pathological response
logical evidence of invasive tumour cells
l evidence of invasive disease of any extent
ant cells but no reduction in overall numbers as compared with the
pre-treatment biopsy
ive tumour cells but overall cellularity still high (<30%)
of in tumour cells up to an estimated 90% loss (30-90%)
mour cells such that only small clusters of widely dispersed cells could
be detected (>90%)
, i.e., only in situ disease or tumour stroma remained
tal or near total therapeutic effect
an 50 % therapeutic effect but less total and near total
n 50% therapeutic effect, but effect event
No therapeutic effect
No residual tumour
e tumour but presence of residual in situ carcinoma
imal residual invasive tumour (<10%)
effect with residual invasive tumour (10-50%)
ic effect but >50% residual invasive tumour
No pathologic response
Point assignments
ologic stage Tumour marker
0; I = 0 ER negative =1 G34 =1
; IIIA/B = 1
IIIC = 2
ade by M.D. Anderson Center (MDACC)
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Cx46, hormone receptor status, HER2 status, pre-
chemo tumour size, proliferation, pathological re-
sponse, stage and grade which did not correlate directly
with each other. Results were considered statistically
significant at p-values of <0.05. Bonferroni correction
was not applied.
Results
Connexin expression before and after neoadjuvant
chemotherapy
Connexin expression upon chemotherapy showed dy-
namic but differential changes related to the isotypes
which is also revealed in details for individual cases in
(Figure 1). Examples of related connexin immunofluores-
cence are seen in Figure 2. In the whole patient cohort,
the number of Cx26 expressing tumours and the percent-
age of Cx26 positive tumour cells in individual tumours
significantly decreased after chemotherapy. The number
of cases scoring 0 increased from 3% to 25% (p <0.001),
while the number of cases scoring 3 decreased from 32%
to 10% (p <0.006). The frequency of intermediate scores
(1 and 2) did not change during therapy. Cx32 expression
was significantly reduced after chemotherapy. The fre-
quency of cases scoring 0 (negative) increased from 10%
to 49% (p <0.004) while of those scoring 1 (weak positive)
decreased from 35% to 17% (p <0.043). The frequency ei-
ther of Cx43 or Cx46 positive cases did not differ signifi-
cantly before and after chemotherapy, though, the number
of 3+ Cx46 positive cases showed a tendency of increase
post-chemotherapy. Of 64 matched samples 50 (for Cx43
51 cases) could be assessed reliably. Cx26 and Cx32 were
mainly decreased, Cx43 showed the least change while
Cx46 levels showed an increasing tendency upon chemo-
therapy (Figure 1B-E).
Correlation of connexin expression with
clinicopathological parameters before and after
neoadjuvant chemotherapy
Correlations between connexin expression, cell proliferation
and clinicopathological features are summarized in Table 3.
Cx26 expression in cases of <5% positive tumour cells
(score 0) post-chemo statistically correlated with improved
overall survival (p=0.011) compared to those of >5% Cx26
positive tumour cells (scores 1–3) (Figure 3). However,
Cx26 expression did not show correlation with other
clinicopathological parameters when using the Spearman
rank (ρ) test. At the same time, Cx32 expression had a
positive correlation with HER2 status both pre-chemo
(ρ=0.31) and a negative correlation to pathological tumour
stage (pT) (ρ =−0.29). Moreover, post-chemo Cx32 and
Ki67 expression showed a positive correlation (ρ=0.46).
Pre-chemo Cx43 expression positively correlated with ER
and PR expression both pre- and post-chemo and withthe clinical tumour stage (cT) (ρ=0.29-0.36) and had
a negative correlation with HER2 status pre-chemo
(ρ=−0.27). Cx46 expression pre- and post-chemo had a
positive statistical correlation with nodal status (pN)
(ρ=0.39 and 0.32) and pre-chemo Cx46 and Ki67 expres-
sion negatively correlated with each other (ρ=−0.29). A
negative correlation was found between ER and Ki67 ex-
pression both pre- and post-chemo (ρ=−0.35- -0.46) and
between PR and Ki67 expression pre-chemo (ρ=−0.45; -0
.52). Furthermore, Ki67 expression had a positive correl-
ation with HER2 status both post-chemo (ρ=0.26) and a
positive correlation was detected between pre-and post-
chemo Ki67 scores (ρ=0.46).
Correlation between the defined clinicopathological
response groups and overall survival
Primary breast cancer cases were classified according
NSABP, Miller-Payne, Sataloff, EWGBSP, CPS-EG
systems. Only the CPS-EG classification showed correl-
ation with overall survival: cases with scores 1 and 2 had
significantly better survival rate (p=0.015) than those
scoring 3, 4 and 5 (Figure 4).
Overlap among subgroups of the classification systems
We also tested how subgroups of the classification
systems overlap in our patient cohort (Figure 5A). In
general, only few cases fell into the subgroups with edge
categories such as EWGBSP TR1a-b and TR3; CPS-EG
1 and 5; Sataloff TA and TD; or Miller-Payne GI and
G5. These included the particularly responsive and the
barely/non-responsive tumours which highly overlapped
among classifications. The rest of cases were heteroge-
neously sorted into the intermediate categories including
EWGBSP TR2a-TR2c; CPS-EG 2-4; Sataloff TB and TC;
and the Miller-Payne G2-G4. The NSABP is a binary sys-
tem without intermediate subgroups based on the pres-
ence or lack of residual tumours. Five cases fell into the
pCR group of NSABP, the rest (84 cases) were assigned to
the pINV group.
Prognostic potential of connexin expression on residual
tumour classifications
We analysed Cx26, Cx32, Cx43 and Cx46 expression within
each classification subgroup in correlation with overall sur-
vival. Due to the Gaussian distribution of cases within the
used classifications and the high agreement either within
the good or the bad prognostic subgroups at the edge cat-
egories we focused on the intermediate subgroups.
Cases with 2+ and 3+ pre-chemo Cx46 expression
(>20%) had significantly better survival rates in
EWGBSP TR2b (p=0.006), Sataloff TB (0.005) and
Miller-Payne G3 (p=0.002) subgroups, than those scor-
ing 0 or 1+ (<20%) for Cx46. This correlation was almost
the same for post-chemo Cx46 expression. In the
Figure 1 Expression of connexin isotypes in breast cancers before and after neoadjuvant chemotherapy (A). Dynamic changes in
connexin isotype expression in the 50 (in Cx43, 51) matched breast cancer samples upon treatment (B-E). Cx26 (B) and Cx32 (C) levels mostly
decreased, Cx43 (D) levels revealed the least change, while Cx46 (E) levels were mainly increased. Green lines represent decrease, red lines
highlight increase. Violet symbols alone represent no change in expression.
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pression (>20%) had significantly better survival rates
(p=0.029) than those scoring 0 and 1+ (<20%). In the
Miller-Payne G3 category the tumours with 1-3+ Cx46
expression (>5%) showed significantly better survival
(p=0.012) than those scoring 0 (<5%). In the EWGBSP
TR2b group the tumours with 2+ and 3+ Cx46 scores
showed nearly significant (p=0.059) better survival
compared to cases scoring 0 and 1+ (Figure 6).
Cases with <5% Cx26 positive cells (score 0) had signifi-
cantly better survival rates in NSABP pINV tumours than
those with >5% (score 1+, 2+, 3+) Cx26 positive cells
(p=0.013). Intermediate categories in the other subgroups
also showed the same tendency but without statisticalsignificance including EWGBSP TR2b (p=0.08), Sataloff
TB (p=0.092), Miller-Payne ‘G2’ (p=0.053) and CPS-EG 4
(p=0.06).
Prognostic potential of Cx26 and Cx46 in the whole
patient cohort and in the subgroups
Using Kaplan-Meier estimates supported by log-rank
test the expression of post-chemo Cx26, ER and PR sta-
tus, pre- and post-chemo Cx46 as well as the CPS-EG
classification showed statistical correlation with overall
survival. Those features which were not correlated with
each other among these when using the chi-square test
were involved in multivariate Cox-regression analysis
(Table 4). HER2 status, proliferation, grade, stage, pre-
Figure 2 Immunofluorescence detection of Cx26, Cx32, Cx43, Cx46 (Alexa 546, red) and Ki67 (Alexa 488, green) in invasive ductal
breast cancers prior to (pre-) and after (post-) neoadjuvant chemotherapy. Cell nuclei were stained using Hoescht (blue). Punctuate cell
membrane associated and cytoplasmic Cx26 (1st row) and Cx32 (2nd row) levels and the proliferating (green) tumour cell fractions were reduced
after neoadjuvant therapy in cases originally scoring 3+. Cx43 (3rd row) and Cx46 (4th row) levels did not change after neoadjuvant chemotherapy
in cases of high scores (3+). Pre-chemotherapy Cx43 and post-chemotherapy Cx46 samples are not stained for Ki67.
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lularity) did not correlate with overall survival, therefore,
they were omitted from further analysis.
In the whole patient cohort, cases with hormone re-
ceptor positivity after chemotherapy had a significantly
improved overall survival (pER=0.012, pPR=0.002). Post-
chemo PR and ER showed a better independent prog-
nostic value according to the multivariate analysis than
post-chemo Cx26 levels and CPS-EG which latter two
were statistically not significant (Table 4).
In the intermediate prognostic categories (EWGBSP
TR2b, Sataloff TB and Miller-Payne G3) none of the
tested parameters correlated with overall survival pre-chemo except Cx46pre, which thus proved to be the only
potential prognostic factor. Post-chemo, only PR positive
cases had a significantly better overall survival in the
EWGBSP TR2b (p=0.03), Sataloff TB (p=0.05) and
Miller-Payne G3 (p=0.006) subgroups. However, none of
these markers proved to be significant independent
prognostic factors in multivariate Cox-regression ana-
lysis (Table 4).
Discussion
Neoadjuvant chemotherapy is now considered as one of
the standard options in the treatment of locally
advanced and also for primary operable breast cancers
Table 3 Correlations of connexin and Ki67 proliferation marker expression with clinicipathological parameters
Cx43 Cx26 Cx32 Cx46 Ki67
pre post pre post pre post pre post pre post
ER pre 0.30 x ns x ns x ns x −0.46 −0.35
ER post 0.36 ns ns ns ns ns ns ns −0.40 −0.38
PR pre 0.34 x ns x ns x ns x −0.45 x
PR post 0.33 ns ns ns ns ns ns ns −0.52 ns
HER2 pre −0.27 x ns x 0.31 x ns x ns x
HER2 post ns ns ns ns ns ns ns ns ns 0.26
cT pre 0.29 x ns x ns x ns x ns x
cN pre ns x ns x ns x ns x ns x
pT post ns ns ns ns −0.29 ns ns ns ns ns
pN post ns ns ns ns ns ns 0.39 0.32 ns ns
grade pre ns x ns x ns x ns x ns ns
Ki67 pre ns x ns x ns x −0.29 x x 0.46
Ki67 post ns ns ns ns ns 0.46 ns ns 0.46 x
ns: not significant; x: not relevant; pre: prior to chemotherapy; post: after chemotherapy.
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established to assess the pathological response and prog-
nosis after systemic primary therapy. These consider
pathological features such as the percentage of residual
tumour cells, the presence or absence of in situ compo-
nent with or without considering nodal status [3,5-8].
Reliable biomarkers to assess response to primary sys-
temic therapy are not yet available. Connexins may
function as gap junctions or hemichannels in the
cell membranes or through intra-cytoplasmic protein
interactions and play fundamental roles in cell homeo-
stasis including cell cycle control [11,16]. In this study
we analysed the expression of four connexin isotypes
Cx26, Cx32, Cx43 and Cx46, and Ki67 for cellFigure 3 Kaplan-Meier plot of overall survival based on Cx26
expression after chemotherapy. Log-rank test reveals significant
association (p=0.011) between reduced Cx26 expression (0; <5%)
and improved disease outcome.proliferation prior to and after neoadjuvant chemotherapy
in breast cancer in correlation with clinicopathological
parameters, overall survival and pathological response
based on current classification systems.
Our main results suggest that increased Cx46 positiv-
ity either pre- or post-chemotherapy and reduced Cx26
expression post-chemotherapy may separate prognostic-
ally more favourable subgroups within the intermediate
categories of the classifications including Miller-Payne
G2-3, Sataloff TB, EWGBSP TR2b and CPS-EG 4
(Figure 5B). In addition, pre-chemotherapy only Cx46
expression appeared to correlate with overall survival.
Others have also observed that biomarkers such as PR,
HER2, grade, or tumour size did not necessarily correl-
ate with prognosis either before or after chemotherapy
[31]. In agreement with those who showed elevated
Cx26 expression to contribute to carcinogenesis in pan-
creatic and prostate carcinoma [32,33] we also found a
significantly reduced Cx26 expression after chemother-
apy in association with better overall survival in breast
cancer (p=0.011). Moreover, decreased Cx26 expression
after chemotherapy could be more promising for prog-
nosis than classical features such as HER2 expression,
grade, Ki67 index according to our results. Interestingly,
loss of Cx26 expression has also been implicated in
reduced survival in primary gastric and colorectal car-
cinomas, suggesting an organ specific biological signifi-
cance of Cx26 [34,35].
The role of connexins in breast cancer development,
progression and metastatic growth has been the subject
of only few previous studies all focusing on primary
breast cancers [21-23,36]. The transitional loss of Cx43
has been reported where re-expression of Cx43 might
sensitize breast cancer cell lines for chemotherapeutic
Figure 4 Kaplan-Meier plot of overall survival based on the
CPS-EG classification. Cases scoring 1–2 show significantly
improved overall survival (p=0.015) compared to those scoring 3–5.
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expression of Cx26, Cx32 and Cx43 have been found
more often in node positive than node-negative breast
cancers [21,22]. Although, Cx46 has been implicated in
protecting MCF-7 breast cancer cells from hypoxia,
apart from our study, there has been no data revealed
on the prognostic role of Cx46 in breast cancer [24].
Increased Cx26 and Cx43 levels have also been
associated with breast cancer metastasis [22]. However,
the prognostic and predictive role of connexins inFigure 5 Distribution of the studied patient cohort within current cla
discriminate good and poor prognostic groups within the equivocal c
MDAAC CPS-EG systems that are used for assessing response to neoa
levels correlate with good prognosis (B).relation to neoadjuvant chemotherapy has not been
investigated before.
Gap junctions are thought to inhibit cell cycle though
most findings relate to Cx43 [19]. Forced Cx43 expression
can block G1/S phase transition or delay G2/M transition
through increasing p21waf1 and reducing Cdk2 levels [37].
Also, Cx43 expression and gap junction coupling can be
reduced through phosphorylation by Cdk1/cyclinB com-
plex at G2/M transition [19]. Therefore, Cx expression
may dynamically change during cell cycle. In breast cancer
cell lines low levels of Cx26 at G1/S phase, increasing
levels during late S/G2 phase transition and down-
regulation in M phase was observed [38].
The correlations we have revealed between Cx expres-
sion and hormone receptor, HER2 or Ki67 levels suggest
that connexin isotypes are differentially involved in the
regulation of breast cancer cell functions. In concord-
ance with published data we found a positive correlation
between Cx43 expression and hormone receptor levels
both before and after treatment in primary breast cancer
[39]. However, either Cx43 or Cx26 protein can be
elevated again in the lymph node metastasis of invasive
breast cancer [22]. We also found a positive correlation
between Cx32 and HER2 expression and between Cx32
and Ki67 expression; and a negative correlation between
Cx43 and HER2 levels and between Cx46 and Ki67 ex-
pression. As expected, Ki67 expression showed a nega-
tive correlation with hormone receptor expression and a
positive correlation with HER2 levels. These results may
imply potential tumour suppressive functions for Cx43
and Cx46 in primary breast cancer as opposed to Cx26ssifications and the power of Cx26 and Cx46 expression to
ategories of NSABP, Miller-Payne G, Sataloff T, EWGBSP TR and
djuvant chemotherapy (A). Both high Cx46 levels and low Cx26
Figure 6 Kaplan-Meier plot of overall survival based on Cx46 expression pre- and post- chemotherapy according to the morphological
response rate assessed using the EWGBSP TR2b, Sataloff TB and Miller-Payne G3 classifications. Elevated Cx46 expression both pre- and
post-chemotherapy is associated with significantly better (p=0.002-0.05) overall survival in all of these categories.
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well. The positive correlation between Cx46 levels and
nodal status may be explained by the lack of correlation
between nodal status and overall survival in our cohort
and that the majority of our cases were ER positive.
In this study, reduced Cx26 and Cx32 levels and
elevated Cx46 expression upon chemotherapy may also
reflect the efficiency of chemotherapy. The exact role of
connexins in carcinogenesis and metastasis formation is
controversial or more probably context dependent.Table 4 Multivariate Cox-regression analysis of connexin
expression, hormone receptors and CPS-EG classification
in breast cancer patient groups
Patient group Parameters P-value HR 95% CI
Lower Upper
whole cohort Cx26post 0.303 0.450 0.098 2.055
ERpost 0.050 2,739 0.999 7.504
Cx26post 0.157 0.134 0.008 2.173
PRpost 0.027 6.509 1.241 34.140
CPS EG 0.967 0.000 0.000 1.381E26
EWGBSP TR2b Cx46post 0.790 4.400 0.844 22.950
PRpost 0.115 3.809 0.722 20.111
Sataloff TB Cx46post 0.226 3.782 0.439 32.600
PRpost 0.244 2.791 0.496 15.711
Miller-Payne G3 Cx46post 0.104 3.322 0.782 14.105
PRpost 0.075 4.400 0.861 22.481
post: after chemotherapy; HR: hazard ratio; CI: confidence intervals.Several previous studies addressed the changes of bio-
marker expression after primary systemic therapy in
breast cancer [40-43]. Discordance in hormone receptor
status has been reported to vary from 2.5% to ~50% [41-
43]. The same has been found for HER2 status with
altered immunophenotype found in up to 43% of cases
especially when immunohistochemistry was the choice
of assay [42,43]. Although not analysed in detail here, we
found discordant ER/PR/HER2 status in only <10% of
our studied patients after neoadjuvant chemotherapy.
The predictive role of hormone receptors and HER2 sta-
tus in view of partial and complete pathological response
in breast cancer has also been extensively investigated
[44-49]. HER2 positive, ER negative breast cancers with
poor histological differentiation without nodal involve-
ment have achieved better complete pathological response
compared to those with lymph node metastasis [44,46-
50]. In our cohort, ER positive HER2 negative tumours
dominated representing prognostically intermediate cat-
egories. Therefore, we did not correlate hormone and
HER2 expression with partial and complete pathological
response to neoadjuvant therapy.
We have classified clinicopathological parameters in
breast cancers according to five current systems and
could establish a significantly improved overall survival
in cases scoring 1–2 against those scoring 3–5 only
when using the CPS-EG classification. The lack of cor-
relation with overall survival in the rest of classifications
(NSABP, Miller-Payne, Sataloff and EWGBSP) is prob-
ably due to the fact that the majority of our cases fell
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are aware, comprehensive assessment of therapy re-
sponse using the major classifications as we tested here
has not been done so far by others in breast cancer
treated with neoadjuvant therapy.
Conclusion
Although our data are limited by the small sample size,
they support additional studies of Cx26 and Cx46 to fur-
ther refine outcome prediction for the intermediate
groups as defined by currently used classification
systems of pathological response to neoadjuvant chemo-
therapy in breast cancer.
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